The British company finished a three‑year turnaround that revamped its orthopaedic division, cut costs, and lifted growth in its wound management and sports medicine units, following margin pressures from inflation and supply‑chain disruptions.
Sign up here.
Smith & Nephew also plans to further simplify its portfolio and reduce inventory by around $500 million under a new strategy, it said in December, while investing in higher-growth areas such as sports medicine.
The company, which makes orthopaedic implants, wound dressings, and other surgical aids, reported a trading profit of $1.21 billion for the year ended December 2025, up 15.5% year-on-year, and in line with market expectations.
Reporting by Yamini Kalia in Bengaluru; Editing by Rashmi Aich
UK medical products maker Smith & Nephew expects 8% profit boost in 2026
